Trial Profile

Phase 1/2 Study of the Safety, Reactogenicity, and Immunogenicity of a Supplemental Spike & Nucleocapsid-targeted COVID-19 Vaccine to Enhance T Cell Based Immunogenicity in Participants Who Have Already Received Prime + Boost Vaccines Authorized For Emergency Use

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs COVID-2019 vaccine-ImmunityBio (Primary) ; COVID-2019 vaccine-ImmunityBio (Primary) ; COVID-2019 vaccine-ImmunityBio (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacodynamics
Sponsors ImmunityBio

21 Feb 2025 Planned primary completion date changed from 1 Mar 2022 to 1 Dec 2021.
14 Dec 2021 Status changed from not yet recruiting to withdrawn prior to enrolment, because the sponsor has changed the development plans which is not for safety reasons.
02 Dec 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Mar 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com